Diagnostics for antiphospholipid syndrome following early-onset fetal growth restriction: A retrospective cohort study

Abstract

Get full access to this article

View all access options for this article.

References

Gibbins

Tebo

Nielsen

, et al. Antiphospholipid antibodies in women with severe preeclampsia and placental insufficiency: a case-control study. Lupus 2018; 27(12): 1903–1910. DOI: 10.1177/0961203318787035, Epub 2018 Jul 20. PMID: 30028257; PMCID: PMC6085160.

Izhar

Ala

Husain

, et al. Anti-phospholipid antibodies in women presenting with preterm delivery because of preeclampsia or placental insufficiency. J Turk Ger Gynecol Assoc 2021; 22(2): 85–90. DOI: 10.4274/jtgga.galenos.2021.2020.0143, Epub 2021 Feb 26. PMID: 33631871; PMCID: PMC8187972.

Rai

Cohen

Dave

, et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314(7076): 253–257. DOI: 10.1136/bmj.314.7076.253, PMID: 9022487; PMCID: PMC2125731.

Gordijn

Beune

Thilaganathan

, et al. Consensus definition of fetal growth restriction: a Delphi procedure. Ultrasound Obstet Gynecol 2016; 48(3): 333–339. DOI: 10.1002/uog.15884, PMID: 26909664.